Docetero 80mg injection

The human body reacts differently to Docetero 80mg injection. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Docetero 80mg injection are mentioned below:

• Headache
  
• Nausea
  
• Unusual tiredness
  
• Anemia
  
• Insomnia
  
• Dizziness
  
• Shortness of breath
  
• Irregular heartbeat
  
• Chest pain
  
• Fatigue Allergic reaction
  
• Upset stomach
  
• Trouble sleeping
  
• Memory problems
  
• Low blood sugar
  
• Vomiting
  
• Abdominal cramps
  
• Swelling of the mouth, face, tongue, or throat

Take the dose of Docetero 80mg injection as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor.

Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. The doctor will provide emergency medical treatment.

Take a dose of Docetero 80mg injection every day at the same time and in the amount recommended by the doctor to get maximum benefit from the medicine. To make it more effective, take a balanced diet and take an adequate amount of vitamins and minerals while on treatment with Docetero 80mg injection.

An anticancer medication, Docetero 80mg injection, works by interacting with the normal functioning of microtubular structures, which are known to play an important role in the multiplication and proliferation of cancer cells. As a result, the growth of cancer cells slows and eventually Docetero 80mg injection kills the cancer cells.

In case you miss a dose immediately contact your doctor. Do not double the dosage to make up for the missed dose. 

• Fumoleau P. Efficacy and safety of docetaxel in clinical trials. (2025). Am J Health Syst Pharm. 54(24 Suppl 2):S19-24 - https://pubmed.ncbi.nlm.nih.gov/9435929/
• Liu DG, Peng RJ, Feng FY, Hu XH, Tang GD, Xiong JP, Zhao HY, Guo Y, Guan ZZ. (2024). Randomized controlled trial of two kinds of home-produced docetaxel in China for advanced breast cancer. Ai Zheng. 25(12):1557-60. Chinese - https://sysu.cnpereading.com/zh/publications/randomized-controlled-trial-of-two-kinds-of-home-produced-docetax/
• Minish Mahendra Jain et al. (2023). Phase I study of docetaxel injection concentrate for nano-dispersion (DICN), a novel polysorbate 80-free formulation of docetaxel.. JCO 30, 2592-2592 - https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.2592
• Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N. (2023). Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Chemotherapy. 51(2-3):154-61.
• Qun Sun. (2024). Bioequivalence study of BH009 and Winthrop (docetaxel) injection (an authorized generic drug of Taxotere) in patients with advanced solid tumors: An open-label, randomized, single-dose, two-way crossover evaluation. JCO 41.
• Tashiro H, Mashino K, Shibahara K, Endo K, Fujii K, Ninomiya M, Ikeda T, Sakata H. (2023). The efficacy and safety of docetaxel for elderly advanced breast cancer patients. Gan To Kagaku Ryoho. 34(3):453-5.
• Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA. (2024). Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemother Pharmacol. 46(6):442-8.
• Wang ZP, Sun Y, Zhang XR, Zhang MH, Wang XW, Yu XJ, Nan KJ, Li EX, Liu JW, Gao YJ, Guan XQ, Song SP, Sheng LJ, Wang DL, Wang ZX. (2024). Docetaxel in the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 28(6):468-70. Chinese.